Respiratory One PAP
The pcg respiratory panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections including SARS-CoV-2 and 20+ other respiratory pathogens.
Respiratory One PAP Panel Menu
Performance: 100% sensitivity and 99.8% specificity
Sample Type: Nasopharyngeal swab
Methodology: Real-Time PCR
Influenza A (subtype) H3
Influenza A (subtype) H1
Influenza A (subtype) H1-2009
Parainfluenza virus 1
Parainfluenza virus 2
Parainfluenza virus 3
Parainfluenza virus 4
Respiratory syncytial virus
Bordetella parapertussis (IS1001)
Bordetella pertussis (ptxP)
COVID-19 and the Value of the Syndromic Approach
Study results suggest higher rates of co-infection between SARS-CoV-2 and other respiratory pathogens than previously reported. In some cases, as many as 20% of COVID-19 patients have co-infections with another respiratory virus.3 Because respiratory symptoms are similar and overlapping, a syndromic panel can provide fast, comprehensive answers and take the guesswork out of choosing which pathogens to test for.
Molecular Assay Panel
For negative results PCG Molecular will send your patients an email on your behalf within 24 hours if patient results are negative for “watch” or high risk results. Being placed on a watch is no reason for patients to panic. It doesn’t mean they have COVID-19 or that they will ever get it. All it means is that we need to watch their cases more closely. We will send you a report and give you a sample letter to send to your patients that communicates the results and what next steps to follow. for positive results. You will receive a detailed report for those patients that test positive for any viral related pathogens. These patients may require additional tests after treatment, along with a personal call. We can advise you of next steps and referrals if you need them.